Abstract -Monoclonal antibodies capable Of recognizing glycosaminoglycan (GAG) fine structures are likely to be of immense value in isolating and characterizing GAG chains with specific functional domains. We previously described the characterization of a monoclonal antibody directed against the chondroitin sulfate moiety of chick embryo fibroblast proteoglycan. This antibody is highly specific for GlcA(2-S04)~1-3GalNAc(6-S04), the minor disaccharide unit occasionally found in some chondroitin sulfate chains. More recently, we have prepared a monoclonal antibody (HK-249) to the heparan sulfate moiety of EHS-tumor proteoglycan. This antibody recognizes a fine structure which is abundant in the tumor heparan sulfate but rare in heparan sulfate preparations purified from healthy mammalian tissues. Chemical parameters of various heparan sulfate preparations and their respective activities suggest that the exceedingly high concentration of non-)-sulfated GlcNS03 residues in the tumor heparan sulfate plays an important role.
INTRODUCTION
Proteoglycans are macromolecules composed of sulfated glycosaminoglycan (GAG) chains that are covalently attached to protein. Species differ with regard to the nature of the core protein and the amount and type of GAG chains ( Fig.1 ) (for reviews see refs. [1] [2] [3] [4] [5] [6] . In multicellular organisms the nearubiquitous distribution of these components in the extracellular matrix, on the cell surface, or inside intracellular granules, suggests their involvement in a wide range of biological processes, including cell proliferation, cell migration, extracellular matrix deposition, cell-matrix interaction, and tissue morphogenesis and repair. Several rare proteoglycans probably involved in specific nonstructural functions have also been described, 2.9. the precursor for Alzheimer's disease-related amyloid protein (refs. 15, 16) , the invariant chain that associates with mouse class I1 major histocompatibility gene products (ref. 1 7 ) , and the type I11 TGF-6 receptor (ref. 18). These findings raise interesting questions about the possible occurrence in either the core protein or GAG moieties of specific determinant groups which may well be related to the potentially important functions associated with proteoglycans. Recent studies have shown that some of the interactions of proteoglycan with other substances are mediated by the protein moiety. For example, the large aggregating cartilage proteoglycan (Fig. 1 , a) contains a hyaluronic acid-binding domain and a domain that functions as a lectin capable of binding simple sugars (ref. 7) . A similar hyaluronic acid-binding domain is present in the large fibroblast proteoglycan ( Fig. 1, b) (ref. 8 ) and in a lymphocyte membrane proteoglycan which mediates lymphocyte binding to the high endothelium of venules in lymphoid organs (refs. 1 9 , 2 0 ) . The binding of a small fibroblastproteoglycan to fibronectin and collagen (ref. 2 1 ) and the binding of TGF-@ to type I11 receptor proteoglycan (ref. 1 8 ) also appear to be of the core protein-dependent kind. Rapidly increasing amounts of research activity aiming at the elucidation of core protein structure will make it possible to identify novel functional domains involved in proteoglycan core protein moieties. Fig. 1 antithrombin 111, heparin cofactor 11, tissue plasminogen activator). Some of these reactivities are likely to depend on specific sugar sequences or sulfation pattern in the GAG structure (for reviews see refs. 3 , 4 and 6).
The early work of Meyer and many others (for a review see ref. 2 2 ) have established the structure of the basic repeating units of every known group of sulfated GAGS. It is obvious however that the knowledge of their basic features (or average structures) provides little basis for understanding the potential abilities of sulfated GAGS which may be of biological importance. Much more detailed information on the fine structure of GAG molecules is needed. In the present communication, we summarize the results of our recent studies utilizing monoclonal antibodies that specifically recognize GAG fine structure, offering a clue to the problem concerning the structure-function relationship of GAG chains.
STRUCTURAL DIVERSITY OF GLYCOSAMINOGLYCANS
In the late 1 9 5 0~~ the sulfated GAGS composed of alternating hexuronic and hexosaminidic groups were classified as chondroitin sulfate A, B, and C (subsequently designated chondroitin 4-sulfate, dermatan sulfate, and chondroitin 6-sulfate, respectively), heparitin sulfate (subsequently designated heparan sulfate), and heparin. At that time the chondroitin sulfate A, B, and C were regarded as isomeric polymers differing only in C5-epimerization (D-glucuronic for A and C, and L-iduronic for B ) or in the position of the sulfate residues (g-acetylgalactosamine 4-sulfate for A and B, and 6-sulfate for C). However, it soon became apparent that the structure of these polysaccharides is far more heterogeneous in regard to position and distribution of D-glucuronic and L-iduronic groups and the content and location of sulfate groups. In an attempt to employ definitive degradative enzyme systems to unravel the complexity of chondroitin sulfate structure, Suzuki and coworkers purified two bacterial endoeliminases (designated chondroitinase ABC and chondroitinase AC) and related sulfatases (designated chondro-4-sulfatase and chondro-6-sulfatase) (ref. The structural heterogeneity of heparan sulfatelheparin-type chains has also been widely documented (for a review see ref. 32 ). The heterogeneity arises from a stepwise series of polymer-level modifications of the precursor molecule composed of alternating N-acetylglucosamine and D-glucuronic acid residues (ref. 33). The precursor chains can be uniquely N-sulfated in the glucosaminyl moiety which is the signal for epimerization of glucuronic acid. The polymer is then further modified by 2-sulfation at C3 and c6 on the glucosamine and at C2 on the D-glucuronic or L-iduronic residues. As the extent and location of both epimerization and sulfation are variable, the final products display a high degree of microheterogeneity. 
MONOCLONAL ANTIBODIES THAT SPECIFICALLY RECOGNIZE CHONDROITIN SULFATE FINE STRUCTURES
The microheterogeneity of GAG appears to distinguish this class of biopolymers sharply from the proteins, in which the number of permissible variations seems very limited. Previous attempts to isolate and characterize determinant groups or functional domains of GAGS have been hampered by this structural variability. Taking advantage of the fact that animals preferentially make antibodies to the regions of biopolymers which may vary from species to species, we have examined the possibility that a series of monoclonal antibodies may be produced against the atypical structures contained in chondroitin sulfate/dermatan sulfate-type chains (see Figs. 2, 3 ). Such antibodies may find application in selectively isolating a subpopulation of GAG chains or oligosaccharide fragments with a specific determinant group, thus allowing us to look at their structure and function in more detail.
When we started on this study (%1983), it was generally accepted that chondroitin sulfate in its native state is effectively non-antigenic, so to elicit an immune response it must in some way be modified. Since, however, the GAG preparations used in those studies should have a wide range of microheterogeneity, there is an alternative possibility that the epitope recognized by this antibody resides in an atypical structure rather than the common disaccharide repeat structure. unit is foreign to the BALB/c mouse (recipient), as it is absent from the chondroitin sulfate prepared from the whole body of a BALB/c mouse. 
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PREPARATION OF A MONOCLONAL ANTIBODY (HK-249) AGAINST A HEPARAN SULFATE-ASSOCIATED EPITOPE THAT IS HIGHLY EXPRESSED IN A M O U S E TUMOR BUT SCARCELY I N NORMAL TISSUES
Approaches to the structural study of heparan sulfate-type GAGS have included chromatographic separation of different types of GAG followed by enzymatic and chemical degradation of the resulting heparan sulfate fraction to small oligosaccharide fragments for identification. Although these approaches have proved useful for demonstrating both similarities and differences among different heparan sulfate preparations in their average structure, further progress in the elucidation of heparan sulfate fine structure or functional domain has been limited, owing to the lack of techniques that enable high resolution of heparan sulfate chains based on differences in fine structure or functional domain. One notable exception is the elucidation of the saccharide sequence in heparin that binds to antithrombin 111, L.E. in 1 9 7 6 , three groups independently showed that only about one-third of the molecules in commercially available heparin preparations bound with high affinity to immobilized antithrombin I11 (refs. 38-40). Subsequent structural analysis has shown that the high affinity binding to antithrombin I11 is mediated by a unique pentasaccharide sequence, in which a novel 3-2-sulfated 3-sulfoglucosamine residue is an essential component (ref. 33) . This discovery provided a useful idea as to how to approach more closely the problem of GAG structure-function relationships. Thus, recent studies using an antithrombin I11 affinity column have shown that antithrombin-binding regions are not restricted to heparin but also occur in heparan sulfate-type chains (refs. 41, 42). Interestingly, the high-affinity chains in endothelial cell heparan sulfate amount to only a few per cent of the total polysaccharide, but they account for practically all of the anticoagulant activity and the 3-0-sulfated glucosamine residues of the starting material (ref.
41).
Previous study of M0-225 monoclonal antibody (see above) suggested that, if heparan sulfate-type GAGS contain atypical fine structures, a series of monoclonal antibodies might be produced, directed against those atypical structures. In 1986, we (ref. 43) and Kure and Yoshie (ref. 44) independently prepared monoclonal antibodies against heparan sulfates (designated HK-249 and HepSS-I, respectively). The heparan sulfate proteoglycan prepared from mouse EHS-tumor was used for the immunization of rats for HK-249 production and the fibrosarcoma cells from methylcholanthrane-induced mouse for the immunization of mice for HepSS-I production. Subsequent studies of the antigen specificity of HepSS-1 showed that the antibody reacts with bovine kidney heparan sulfate and to a lesser degree, with heparin (ref. 45 ). This would indicate that the HepSS-I epitope resides in a typical saccharide structure, i.g. the common structure predominantly found in ordinary heparan sulfate preparations. Since, however, the concentration of the heparan sulfate sample required for a 50 % inhibition of HepSS-1 binding to the immunogen (fibrosarcoma cell) is very high (1.2.5 mg/ml) and since the nature of antigen (heparan sulfate proteoglycan ? ) on the fibrosarcoma cell surface has not been described, the definitive structure of the HepSS-1 epitope, whether typical or atypical, remains to be determined. Our studies of HK-249, on the other hand, have shown that it specifically recognizes a heparan sulfate-associated epitope that is highly expressed in the EHS-tumor but to a far lower degree in normal tissues (Fig. 4) . The heparan sulfate from EHS-tumor is unique in that, whereas 6-2-sulfate groups are scarce, the ;-sulfate content is significantly above the range for the heparan sulfates prepared from normal tissues. One could predict then that this unique structural feature is associated with the immunological properties of EHS-tumor heparan sulfate. The importance of 8-sulfate groups has indeed been shown by chemical modification of EHS-tumor heparan sulfate, -i.e. removal of 8-sulfate groups resulted in a complete loss of the reactivity to HK-249 which was restored by resulfation but not by acetylation of the exposed free amino groups. That the scarcity of 6-2-sulfate groups is essential for an optimal reactivity has been indicated by the observations that chemical 2-sulfation of EHS-tumor heparan sulfate predominantly at C6 of the glucosamine residues resulted in an appreciable weakening of the reactivity, whereas partial de-)-sulfation caused heparin or bovine kidney heparan sulfate (which otherwise had little or no reactivity) to become somewhat more reactive. Thus, the chemical parameters of heparan sulfates and their respective reactivities suggest that the exceedingly high concentration of 8-sulfated, non-)-sulfated glucosamine residues in the tumor heparan sulfate species plays an important role in the HK-249 recognition. However, pending the actual isolation of a determinant group or functional domain from EHS-tumor heparan sulfate, any prediction as to the structure of the recognition determinant must be regarded as tentative.
SEPARATION OF HIGH-A N D LOW-AFFINITY HEPARAN SULFATE SPECIES BY AFFINITY CHROMATOGRAPHY O N IMMOBILIZED HK-249
As Fig. 5 shows, our affinity column complexed with HK-249 antibody separates EHS-tumor heparan sulfate into two species, one with low affinity for HK-249 and one with high affinity. The high-affinity species accounts for about 23 % of the applied material.
After dialysis, when this high-affinity fraction was reapplied to the column, it was quantitatively bound. To ensure that the flow-through fraction was devoid of high-affinity species, the unbound material was passed through the column three times more. By the third application, little or no highaffinity material was seen. The final unbound fraction accounts for about 62 % the starting EHS-tumor heparan sulfate preparation. In contrast to the EHS-tumor heparan sulfate, bovine lung heparan sulfate, when subjected to the HK-249 affinity column, yielded a high-affinity material that accounts for only 1 . 6 % of the applied material. It is notable, however, that this high-affinity material accounted for practically all of the antigenic activity of the starting material. At the present time we have no knowledge of the specific features which distinguish the highaffinity species from the low-affinity one, but further analyses of these distinct species will hopefully reveal the structure of the HK-249 recognition determinant in the heparan sulfate molecules.
Application of the methods illustrated in this study to other GAGS and their partial degradation products might enable production of specific immune reagents useful for the detection and isolation of oligosaccharide species with defined sequences.
